Olema Pharmaceuticals, Inc.
OLMAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Olema Pharmaceuticals, Inc. (OLMA) is listed under Biotechnology. Valued at $560.9M, OLMA is a small-cap name in its sector. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Market Cap
$560.9M
Beta
2.01
P/E (TTM)
—
P/E (Fwd)
-2.43
EPS (TTM)
$-2.12
EPS (Fwd)
$-2.64
ROE
-52.7%
ROA
-31.8%
Cash
$461.1M
Total Debt
$3.7M
Free CF
-$89.1M
52W Change
-27.1%
Annual Financials
Cash vs Debt
Where OLMA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OLMA finished 40.15% below its 150-day moving average ($11.88) and 52.35% below its 200-day moving average ($14.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OLMA overbought or oversold?
At the October 20, 2026 close, OLMA's RSI(14) was 25.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Olema Pharmaceuticals, Inc. holds $461.1M in cash against $3.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$89.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -52.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, OLMA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, OLMA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OLMA.